My Treatment Approach: Androgen Receptor Inhibitors and the Evolving Treatment Paradigm in Castration-Sensitive Prostate Cancer - Episode 2

Risk Stratification and Prognostic Markers in castration-sensitive prostate cancer

June 26, 2024

Stephen J. Freedland, MD, Eleni Efstathiou, MD, PhD

The panel of prostate cancer experts explores risk stratification methodologies and prognostic markers for castration-sensitive prostate cancer, emphasizing crucial factors that influence patient categorization and treatment decisions.

Video Player is loading.

Current Time 0:00

Duration 0:00

Loaded: 0%

Stream Type LIVE

Remaining Time 0:00

EP. 1: Testing Principes and Benefits of Early Intervention in Castration-Sensitive Prostate Cancer

Now Viewing

EP. 2: Risk Stratification and Prognostic Markers in castration-sensitive prostate cancer

EP. 3: Evolving Treatment Paradigm and NCCN Guideline Updates

EP. 4: The EMBARK trial investigating enzalutamide in NM CSPC

EP. 5: The Role of PSA Doubling Time in Risk Assessment

EP. 6: Patient Case 1: Non-Metastatic CSPC with Rapidly Doubling PSA

EP. 7: Patient Case 2: Metastatic CSPC

EP. 8: Final Thoughts on CSPC

Dr. Efstathiou asks Dr. Freedland: What are the key factors you consider in risk stratification of your patients? What clinical characteristics and existing biomarkers help guide your assessment?
What promising biomarkers have emerged that may help detect early signs of prostate cancer progression? (Logan Cancers 2023, Kumaraswamy JCI Insight 2023, please highlight any others)